Clinical Trials Directory

Trials / Completed

CompletedNCT02587793

Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients

Kaohsiung Medical University Chung-Ho Memorial Hospital

Status
Completed
Phase
Study type
Observational
Enrollment
208 (actual)
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The aim of this project is to investigate whether the proliferative speeds of cultured cells using our method can be integrated into Barcelona Clinic Liver Cancer (BCLC) staging classification for the possibility of personalized treatment and prediction the outcomes in hepatocellular carcinoma (HCC) patients.

Detailed description

A total of at least 150 patients will be included and followed for at least one year. The proliferative speeds of cultured cells will be classified into (a) rapid proliferation of HCC cells with or without concomitant rapid proliferation of cancer-associated fibroblasts (CAFs), (b) rapid proliferation of CAFs alone, and (c) slow proliferation three groups. The definition for the rapid proliferation of cultured cells fits at least one of the following two items: (1) growth area of cultured cells at the 15th-28th day \> two times of the growth area measured at the 14th day, or (2) growth area of cultured cells at the 15th-28th day \> 70% growth area of the 25 cm flask. The GraphPad Prism software version 4.03 (GraphPad Software, Inc., La Jolla, CA, USA) is applied for statistical analysis. Influence of the proliferative speeds of cultured cells on survival and cancer progression will be calculated by the logrank test. The statistical significance is defined as P \< 0.05.

Conditions

Interventions

TypeNameDescription
OTHERnot interventional study

Timeline

Start date
2014-10-01
Primary completion
2018-07-31
Completion
2018-07-31
First posted
2015-10-27
Last updated
2019-02-27

Locations

2 sites across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT02587793. Inclusion in this directory is not an endorsement.